- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02575768
Myocardial Flow Reserve in Severe AS Without Obstructive Coronary Artery Disease
Reduced Myocardial Flow Reserve in Exertional Angina With Severe Aortic Stenosis and Normal Coronary Arteries: Insight From Prospective Observational Adenosine-stress Cardiac Magnetic Resonance Imaging Study
Exertional angina is common symptom in patients with severe aortic stenosis (AS) without obstructive coronary artery disease (CAD). Although reduced myocardial flow reserve is one of the proposed explanations for angina, little is known about the pathophysiology.
This study aimed that adenosine-stress cardiac magnetic resonance can be used for the assessment of myocardial perfusion reserve and suggest the pathophysiology of development of angina in patients with severe AS without obstructive CAD.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- severe AS
- normal LV ejection fraction (EF ≥ 50%)
Exclusion Criteria:
- age <18
- LVEF < 50% in echocardiography
- concomitant other valvular disease of moderate or severe severity
- previous aortic valve replacement
- symptomatic patients other than chest pain
- obstructive CAD (>30% luminal stenosis in at least one coronary artery on coronary angiography)
- history of myocardial infarction or acute coronary syndrome
- contraindication to adenosine
- any absolute contraindication to CMR
- estimated glomerular filtration rate <30 mL/min/1.73m2.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Severe AS: asymptomatic
Asymptomatic
|
undergoing adenosine-stress cardiac magnetic resonance imaging
|
|
Severe AS: pure angina
Presence of exertional chest pain
|
undergoing adenosine-stress cardiac magnetic resonance imaging
|
|
Normal controls
Healthy controls
|
undergoing adenosine-stress cardiac magnetic resonance imaging
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Values of the myocardial perfusion reserve index (MPRI)
Time Frame: Day 1
|
Signal intensity-time curves were generated for all segments and the maximum upslope of the LV myocardium divided by the maximum upslope of the LV cavity.
MPRI [upslopestress(corrected)/upsloperest(corrected)] was calculated dividing the segmental upslope value during adenosine and rest.
Whole (average of all myocardial segments) MPRI were calculated.
|
Day 1
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, O'Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM 3rd, Thomas JD; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jun 10;63(22):e57-185. doi: 10.1016/j.jacc.2014.02.536. Epub 2014 Mar 3. No abstract available. Erratum In: J Am Coll Cardiol. 2014 Jun 10;63(22):2489. Dosage error in article text.
- American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons, Bonow RO, Carabello BA, Kanu C, de Leon AC Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation. 2006 Aug 1;114(5):e84-231. doi: 10.1161/CIRCULATIONAHA.106.176857. No abstract available. Erratum In: Circulation. 2007 Apr 17;115(15):e409. Circulation. 2010 Jun 15;121(23):e443.
- Silaruks S, Clark D, Thinkhamrop B, Sia B, Buxton B, Tonkin A. Angina pectoris and coronary artery disease in severe isolated valvular aortic stenosis. Heart Lung Circ. 2001;10(1):14-23. doi: 10.1046/j.1444-2892.2001.00060.x.
- Ahn JH, Kim SM, Park SJ, Jeong DS, Woo MA, Jung SH, Lee SC, Park SW, Choe YH, Park PW, Oh JK. Coronary Microvascular Dysfunction as a Mechanism of Angina in Severe AS: Prospective Adenosine-Stress CMR Study. J Am Coll Cardiol. 2016 Mar 29;67(12):1412-1422. doi: 10.1016/j.jacc.2016.01.013.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Pain
- Neurologic Manifestations
- Pathological Conditions, Anatomical
- Aortic Valve Disease
- Heart Valve Diseases
- Ventricular Outflow Obstruction
- Aortic Valve Stenosis
- Chest Pain
- Constriction, Pathologic
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Vasodilator Agents
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Purinergic Agents
- Purinergic P1 Receptor Agonists
- Purinergic Agonists
- Adenosine
Other Study ID Numbers
- 2012-01-014
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chest Pain
-
Clinical Locomotion ScienceOdense University Hospital; University of Southern Denmark; The County of Funen... and other collaboratorsCompletedUndiagnosed Chest Pain | Musculoskeletal Chest Pain | Non-cardiac Chest PainDenmark
-
Academisch Medisch Centrum - Universiteit van Amsterdam...TerminatedFunctional Chest PainNetherlands
-
Queen's UniversityCompletedChest Pain Atypical SyndromeCanada
-
Ataturk UniversityCompletedPain, Acute | Pain, ChestTurkey
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Yichang Humanwell Pharmaceutical Co., Ltd., ChinaRecruiting
-
Universiti Sains MalaysiaCompletedNon Cardiac Chest PainMalaysia
-
Milton S. Hershey Medical CenterCompletedNoncardiac Chest Pain (NCCP)United States
-
Fayoum University HospitalCompleted
-
University of Texas Southwestern Medical CenterCompletedAcute Chest PainUnited States
-
Massachusetts General HospitalBracco Diagnostics, IncCompletedChest Pain SyndromeUnited States
Clinical Trials on Adenosine-stress cardiac magnetic resonance imaging
-
Weill Medical College of Cornell UniversityRecruitingFriedreich's AtaxiaUnited States
-
Adverum Biotechnologies, Inc.Adverum Biotechnologies SAS, a wholly owned subsidiary of Adverum Biotechnologies...CompletedFriedreich's AtaxiaFrance
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Mayo ClinicCompletedMyocardial StiffnessUnited States
-
RWTH Aachen UniversityHeidelberg UniversityCompletedAcute Myocardial InfarctionGermany
-
Chinese Academy of Medical Sciences, Fuwai HospitalNational Natural Science Foundation of China; Beijing Natural Science FoundationRecruitingMyocardial Infarction (MI) | Ischemic Heart Disease (IHD)China
-
Chinese Academy of Medical Sciences, Fuwai HospitalRecruiting
-
Azienda Ospedaliero, Universitaria Ospedali RiunitiFondazione Toscana Gabriele Monasterio; SICP WG CMR/CTRecruitingTetralogy of Fallot | Cardiac Arrhythmia | Cardiac Event | Cardiac Death, SuddenItaly
-
Centro Medico TeknonRecruitingMyocardial Infarction | Arrhythmias, Cardiac | Ventricular Tachycardia | Ventricular Arrythmia | Sudden Cardiac Death | Myocardial Infarction Old | Sudden Cardiac Death Due to Cardiac ArrhythmiaSpain
-
Chinese Academy of Medical Sciences, Fuwai HospitalNational Heart, Lung, and Blood Institute (NHLBI); Peking Union Medical College... and other collaboratorsRecruitingCardiac Failure | Bundle-Branch Block, Left | ICD/Pacemaker Implantation | Cardiovascular Magnetic Resonance ImagingChina